Connect Biopharma (CNTB) Stock Price, News & Analysis

Company Overview

Connect Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody and small-molecule therapies for immune-mediated diseases. Since its inception, the company has pursued a precision immunology approach, applying advanced screening and antibody engineering technologies to identify targets implicated in inflammatory pathways. Connect Biopharma’s research platform is designed to accelerate the transition of promising candidates from laboratory to clinical testing.

The company’s lead programs include CBP-201, a fully human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), currently in Phase II trials for ulcerative colitis and psoriasis, and CBP-307, an oral sphingosine-1-phosphate receptor modulator in development for inflammatory bowel disease. Both candidates leverage proprietary binding and pharmacokinetic optimization to achieve sustained target engagement while minimizing off-target effects. These pipelines are supported by a robust preclinical portfolio aimed at additional cytokine and chemokine targets.

Headquartered in Hong Kong with research facilities in Shanghai and clinical operations in the United States, Connect Biopharma conducts global studies spanning Asia, Europe and North America. The company maintains strategic partnerships with academic institutions and contract research organizations to advance its therapeutic candidates through regulatory milestones. Its network of external collaborators aids in biomarker development and patient stratification strategies to enhance trial efficiency.

Connect Biopharma’s leadership team comprises seasoned executives and scientific founders with deep experience in immunology, biologics development and global clinical operations. Guided by its mission to bring transformative treatments to patients with chronic inflammatory disorders, the company continues to expand its portfolio and advance novel assets toward commercialization.

Key Stats

• Today's Range: $1.11 to $1.56
• 50-Day Range: $0.73 to $1.52
• 52-Week Range: $0.51 to $1.60
• Volume: 804,408 shs
• Average Volume: 61,074 shs
• Market Capitalization: $84.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Connect Biopharma Stock Analysis - MarketRank™

Connect Biopharma scored higher than 63% of companies evaluated by MarketBeat, and ranked 397th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Connect Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Connect Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Connect Biopharma are expected to decrease in the coming year, from ($0.22) to ($0.32) per share.

Price to Book Value per Share Ratio

Connect Biopharma has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of Connect Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Connect Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Connect Biopharma has recently increased by 66.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Connect Biopharma does not currently pay a dividend.

Dividend Growth

Connect Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of Connect Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Connect Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Connect Biopharma has recently increased by 66.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.43

News Sentiment

Connect Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Connect Biopharma this week, compared to 1 article on an average week.

Search Interest

3 people have searched for CNTB on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Connect Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.72% of the stock of Connect Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CNTB Stock Analysis - Frequently Asked Questions

How have CNTB shares performed this year?

Connect Biopharma's stock was trading at $1.38 at the beginning of the year. Since then, CNTB stock has increased by 10.1% and is now trading at $1.52.

How were Connect Biopharma's earnings last quarter?

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07.

When did Connect Biopharma IPO?

Connect Biopharma (CNTB) raised $150 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO.

How do I buy shares of Connect Biopharma?

Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Connect Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Connect Biopharma investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Builders FirstSource (BLDR) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 9/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNTB
• CIK: 1835268
• Web: www.connectbiopharm.com
• Phone: 18587271045
• Fax: +1 8586147007
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Connect Biopharma: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +360.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 10.25
• Quick Ratio: 10.25

Sales & Book Value

• Annual Sales: $26.03 million
• Price / Sales: 3.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 55,560,000
• Free Float: 43,004,000
• Market Cap: $84.45 million
• Optionable: Optionable
• Beta: -0.20